France: CJEU issues decision on reconditioning by parallel importers

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

France: CJEU issues decision on reconditioning by parallel importers

Sponsored by

beau-de-lomenie.png

Jurisprudence has had fixed rules for a long time on the reconditioning of pharmaceutical products by parallel importers, without the consent of the trade mark owner.

The reconditioning must not affect the original condition of the product. The presentation of the product must not harm the image of the brand and its proprietor. If there is new packaging, it must clearly indicate the person who carried out the reconditioning and the product. Finally, the importer must notify the trade mark owner of the future sale and provide him with, on request, a specimen of the reconditioning.

These conditions allow the trade mark owner to maintain some control over the distribution of his products by parallel importers.

New opportunities for the parallel market are now offered by a decision recently rendered by the Court of Justice of the European Union (CJEU) (decision of the CJEU, May 17 2018 C-642/06).

In this case, the parallel importer added a new label on the pharmaceuticals to permit their importation. The trade mark owner opposed this commercialisation insofar as the importer failed to inform him about this reimport and the new packaging adopted.

The Court noted that in all cases until then the reconditioning had required the opening of the original packaging. Here, the packaging had not been modified, nor the original presentation affected.

The Court made the following points:

(i) the importer had limited himself to affixing an additional label on an unprinted part of the packaging, which had not been opened;

(ii) this label was small and included only the name of the parallel importer, its address and telephone number, a barcode and a pharmacological number.

As a result, affixing such a label did not contravene the trade mark holder's rights, and the parallel importer was not obliged to inform the trade mark holder of his action.

marie.jpg

Aurélia Marie

Cabinet Beau de Loménie

158, rue de l’Université

F - 75340 Paris Cedex 07 France

Tel: +33 1 44 18 89 00

Fax: +33 1 44 18 04 23

contact@bdl-ip.com

www.bdl-ip.com

more from across site and SHARED ros bottom lb

More from across our site

Morgan Lewis adds three partners with technical depth, reinforcing the firm’s strategy to bridge legal and tech expertise in patent litigation
The firm posted a 13% increase in profit as well as a rise in overall revenue
Catherine Lee, one of Managing IP’s Top 250 Women in IP 2025, discusses her ‘soft’ approach to leadership and why building a community at work is important
Transactions specialists at Paul Weiss are advising on the high-profile split of Kraft Heinz into two companies, while Skadden is also involved in the deal
Youngmin Park joins us for our ‘Five minutes with’ series to discuss learning languages, moonlighting as a drummer, and why late is better than never
The record-breaking $1.5 billion settlement between the AI company and book authors may not lead to rapid resolution of other cases, say copyright lawyers
Leaders at two Brazilian law firms outline strategies to adjust to trademark fee changes at Brazil's IP office while urging clients to apply before September 20
Former in-house counsel Andriana Shultz Daly has returned to the firm with client-side insight and courtroom skills to build the firm’s life sciences practice
The LMG Life Sciences Awards announces the 2025 winners for the 13th annual awards!
News of AI company Cerence accusing Apple of patent infringement and a hiring update from Lewis Silkin were also among the top talking points
Gift this article